Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

General

General

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • News

ASLAN Pharmaceuticals Announces Expansion Of Its Collaboration With Zenyaku To Investigate The Biology Underlying Differential Effects Of Eblasakimab Compared To Other Biologics

By Benzinga Newsdesk
May 2, 9:11 AM
New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab.The findings will deepen understanding of

ASLN

Read More
2 minute read
  • General
  • News

Food Giant Kellanova Shines Despite Challenges, Sticks To Annual Guidance

By Shivani Kumaresan
May 2, 9:05 AM
Kellanova outperforms expectations despite a 4.3% year-on-year sales decline, reporting $3.20 billion in first-quarter FY24 sales, surpassing analyst forecasts of $3.16 billion. Despite currency challenges and divestiture impacts, the company maintains strong organic growth, aligning with its long-term objectives.

K

Read More
2 minute read
  • General
  • News

Chubb Braces For Record Shipping Insurance Loss After $350M Payout For Baltimore Bridge Collapse

By Benzinga Neuro
May 2, 8:50 AM
In the wake of Baltimore’s Francis Scott Key Bridge collapse, insurance company Chubb (NYSE:CB) is set to shell…

CB

Read More
2 minute read
  • Biotech
  • General
  • News

Elevai Biosciences Highlights Preclinical Data Showing Potential Of In-Licensed Asset “EL-22” For The Treatment Of Obesity

By Benzinga Newsdesk
May 2, 8:39 AM
Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a

ELAB

Read More
4 minute read
  • Biotech
  • General
  • News

Veru To Present At The GLP-1 Based Therapeutics Summit

By Benzinga Newsdesk
May 2, 8:38 AM
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory

VERU

Read More
2 minute read
  • Biotech
  • General
  • News

Establishment Labs Notes Presentation Of 4-Year Results From Motiva U.S. IDE Study At The Aesthetic Meeting 2024

By Benzinga Newsdesk
May 2, 8:35 AM
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of

ESTA

Read More
2 minute read
  • Biotech
  • General
  • News

Limoneira’s Joint Venture With The Lewis Group Of Companies Announces The Closing For All Of Phase 2 At Harvest At Limoneira With National Home Builder Lennar

By Benzinga Newsdesk
May 2, 8:32 AM
Phase 2 Closing Consists of 554 Homesites in Harvest; All Acquired by LennarJoint Venture Has Now Closed a Total of 1,261 Residential Homesite Sales at HarvestLimoneira Company (the "Company" or "Limoneira")

LMNR

Read More
1 minute read
  • Biotech
  • General
  • Global
  • News

Akoya Biosciences And Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval For KR-HT5 In China To Support Next Generation Pathology Clinical Workflows

By Benzinga Newsdesk
May 2, 8:19 AM
Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya

AKYA

Read More
2 minute read
  • Biotech
  • General
  • News

bioAffinity Technologies News Update, CyPath Lung Sales Ramp Up Month Over Month

By Benzinga Newsdesk
May 2, 8:15 AM
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))) shares recent Company news.CyPath® Lung Sales Ramp Up Month over MonthSales of CyPath® Lung, our noninvasive diagnostic test for the early detection of lung

BIAF

Read More
2 minute read
  • Analyst Color
  • Equities
  • General
  • Markets
  • News
  • Tech

Despite Surge In Tesla Stock, Investment Director Stresses Concerns Over Fundamentals And Demand: ‘Bottom Line…Fundamentals Are Not Good’

By Benzinga Neuro
May 2, 8:12 AM
Hawtin also highlighted potential demand issues stemming from Tesla's aggressive price cuts, which have led to a drop in used car values and could result in higher leasing costs.

TSLA

Posts pagination

Previous 1 … 142 143 144 … 2,367 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service